BFBIO demonstrated solid growth with a revenue increase to Rs 2.67 billion, while profit after taxation rose to Rs 187.78 million
Filed as: Financial Results for the Quarter Ended 31-12-2025
Summary
BFBIO demonstrated solid growth with a revenue increase to Rs 2.67 billion, while profit after taxation rose to Rs 187.78 million.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Revenue | 2.67 | 1.33 | +100.8% |
| Gross Profit | 1.18 | 0.62 | +90.3% |
| Profit After Taxation | 0.19 | 0.08 | +137.5% |
| Total Assets | 10.03 | 8.16 | +22.9% |
| Total Equity | 5.01 | 4.66 | +7.5% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Revenue rose to Rs 2.67 billion from Rs 1.33 billion, reflecting a growth of 100.1%.
- Gross profit improved to Rs 1.18 billion from Rs 623.00 million, indicating a significant increase in operational efficiency.
- Profit after taxation increased to Rs 187.78 million from Rs 80.54 million, showcasing strong bottom-line growth.
BF Biosciences Limited (BFBIO) on Nafa
Last price Rs 135.48 · Pharmaceuticals · You can own BFBIO shares from your phone.
More BFBIO announcements
- NoticeTransmission of Quarterly Financial Statements for the Period Ended 30-09-2026
- NoticeCertified true copy of the resolutions passed in the Annual General Meeting of the Company
- NoticeAnnual Progress Report for the Year Ended June 30, 2026
- Financial resultBF Biosciences Limited reported a net profit of Rs 184.88 million for the first quarter ended 30 September 2026Filed as: Financial Results for the Quarter Ended 30-09-2026
- NoticeBoard Meeting
- NoticeTransmission of Annual Financial Statements for the Year Ended 30-06-2026
Source: BF Biosciences Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.